Lymphoid aggregates accumulate in the lung during allergen-driven airway inflammation and serve as a local source of IgE production
Lymphoid aggregates (LAs) can develop in the lung in response to infection or chronic inflammation. Allergen-induced inflammation may drive LA formation in inflamed lung, and once established, the presence of pulmonary LAs may serve as a dynamic site of IgE production directly in the mucosal site. Here, we investigate the composition of LA and their role in local IgE+ PCs development after house dust mite (HDM) allergen exposure. We show that short-term allergen exposure (4 weeks) resulted in the generation of LAs composed of B cells, CD4+ T cells and follicular DCs in the lung. IgE+ PCs also accumulated in the lung after short-term allergen exposure and found that over 90% of IgE+ PCs are tissue-resident. Notably, LA are found in close proximity to airway epithelial cells, while IgE+ PCs are localized outside of major lymphoid aggregates. Finally, we demonstrate that chronic exposure to HDM could generate long-lived IgE PCs present in the lung, even when de novo production of IgE was interrupted with either persistent B cell depletion or anti-IL-4Ra to block IgE class switching. These data demonstrate that IgE+ PCs arise during acute HDM exposure in non-lymphoid lung tissues where allergic inflammation is occurring, localize near the airway, and keep accumulating during chronic allergic inflammation. The inflamed lung can thus provide a survival niche for long-lived IgE+ PCs that can contribute to local IgE production.
Authors
- Caroline Sandén (ORCID: https://orcid.org/0000-0003-4836-0892)
- Seblewongel Asrat (ORCID: https://orcid.org/0000-0001-9953-7120)
- Jamie Marie Orengo (ORCID: https://orcid.org/0000-0002-2695-6508)
- André Limnander (ORCID: https://orcid.org/0000-0001-9052-0146)
- Eva Conde García
- Joseph C. Devlin (ORCID: https://orcid.org/0000-0002-0003-4812)
- Gurinder S. Atwal (ORCID: https://orcid.org/0000-0002-0125-6943)
- Matthew A. Sleeman (ORCID: https://orcid.org/0000-0003-2945-0315)
- Jonas S. Erjefält (ORCID: https://orcid.org/0000-0002-6716-3010)
- Wei Keat Lim (ORCID: https://orcid.org/0000-0002-6226-2570)
- Andrew Murphy (ORCID: https://orcid.org/0000-0003-4152-4081)
- Andrea Vecchione (ORCID: https://orcid.org/0009-0000-6314-6822)
Institutions
- Progenics Pharmaceuticals (United States) (US)
Publication Details
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1183/13993003.congress-2024.pa4845
- Primary Topic
- IL-33, ST2, and ILC Pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00